Breast cancer and hormone-replacement therapy in the Million Women Study
- PMID: 12927427
- DOI: 10.1016/s0140-6736(03)14065-2
Breast cancer and hormone-replacement therapy in the Million Women Study
Erratum in
- Lancet. 2003 Oct 4;362(9390):1160
Abstract
Background: Current use of hormone-replacement therapy (HRT) increases the incidence of breast cancer. The Million Women Study was set up to investigate the effects of specific types of HRT on incident and fatal breast cancer.
Methods: 1084110 UK women aged 50-64 years were recruited into the Million Women Study between 1996 and 2001, provided information about their use of HRT and other personal details, and were followed up for cancer incidence and death.
Findings: Half the women had used HRT; 9364 incident invasive breast cancers and 637 breast cancer deaths were registered after an average of 2.6 and 4.1 years of follow-up, respectively. Current users of HRT at recruitment were more likely than never users to develop breast cancer (adjusted relative risk 1.66 [95% CI 1.58-1.75], p<0.0001) and die from it (1.22 [1.00-1.48], p=0.05). Past users of HRT were, however, not at an increased risk of incident or fatal disease (1.01 [0.94-1.09] and 1.05 [0.82-1.34], respectively). Incidence was significantly increased for current users of preparations containing oestrogen only (1.30 [1.21-1.40], p<0.0001), oestrogen-progestagen (2.00 [1.88-2.12], p<0.0001), and tibolone (1.45 [1.25-1.68], p<0.0001), but the magnitude of the associated risk was substantially greater for oestrogen-progestagen than for other types of HRT (p<0.0001). Results varied little between specific oestrogens and progestagens or their doses; or between continuous and sequential regimens. The relative risks were significantly increased separately for oral, transdermal, and implanted oestrogen-only formulations (1.32 [1.21-1.45]; 1.24 [1.11-1.39]; and 1.65 [1.26-2.16], respectively; all p<0.0001). In current users of each type of HRT the risk of breast cancer increased with increasing total duration of use. 10 years' use of HRT is estimated to result in five (95% CI 3-7) additional breast cancers per 1000 users of oestrogen-only preparations and 19 (15-23) additional cancers per 1000 users of oestrogen-progestagen combinations. Use of HRT by women aged 50-64 years in the UK over the past decade has resulted in an estimated 20000 extra breast cancers, 15000 associated with oestrogen-progestagen; the extra deaths cannot yet be reliably estimated.
Interpretation: Current use of HRT is associated with an increased risk of incident and fatal breast cancer; the effect is substantially greater for oestrogen-progestagen combinations than for other types of HRT.
Comment in
-
Breast cancer and hormone-replacement therapy: up to general practice to pick up the pieces.Lancet. 2003 Aug 9;362(9382):414-5. doi: 10.1016/S0140-6736(03)14095-0. Lancet. 2003. PMID: 12927422 No abstract available.
-
Breast cancer and hormone-replacement therapy: the Million Women Study.Lancet. 2003 Oct 18;362(9392):1328-9; author reply 1330-1. doi: 10.1016/S0140-6736(03)14591-6. Lancet. 2003. PMID: 14575984 No abstract available.
-
Breast cancer and hormone-replacement therapy: the Million Women Study.Lancet. 2003 Oct 18;362(9392):1328; author reply 1330-1. doi: 10.1016/S0140-6736(03)14590-4. Lancet. 2003. PMID: 14575985 No abstract available.
-
Breast cancer and hormone-replacement therapy: the Million Women Study.Lancet. 2003 Oct 18;362(9392):1329; author reply 1330-1. doi: 10.1016/s0140-6736(03)14592-8. Lancet. 2003. PMID: 14575987 No abstract available.
-
Breast cancer and hormone-replacement therapy: the Million Women Study.Lancet. 2003 Oct 18;362(9392):1330; author reply 1330-1. doi: 10.1016/S0140-6736(03)14593-X. Lancet. 2003. PMID: 14575988 No abstract available.
-
Breast cancer and hormone-replacement therapy: the Million Women Study.Lancet. 2003 Oct 18;362(9392):1330; author reply 1330-1. doi: 10.1016/S0140-6736(03)14594-1. Lancet. 2003. PMID: 14575989 No abstract available.
-
Breast cancer and hormone-replacement therapy: the Million Women Study.Lancet. 2003 Oct 18;362(9392):1330; author reply 1330-1. doi: 10.1016/S0140-6736(03)14595-3. Lancet. 2003. PMID: 14575990 No abstract available.
Similar articles
-
Endometrial cancer and hormone-replacement therapy in the Million Women Study.Lancet. 2005 Apr 30-May 6;365(9470):1543-51. doi: 10.1016/S0140-6736(05)66455-0. Lancet. 2005. PMID: 15866308
-
Hormone replacement therapy and false positive recall in the Million Women Study: patterns of use, hormonal constituents and consistency of effect.Breast Cancer Res. 2006;8(1):R8. doi: 10.1186/bcr1364. Epub 2005 Dec 23. Breast Cancer Res. 2006. PMID: 16417651 Free PMC article.
-
Use of HRT and the subsequent risk of cancer.J Epidemiol Biostat. 1999;4(3):191-210; discussion 210-5. J Epidemiol Biostat. 1999. PMID: 10695959 Review.
-
Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence.Lancet. 2019 Sep 28;394(10204):1159-1168. doi: 10.1016/S0140-6736(19)31709-X. Epub 2019 Aug 29. Lancet. 2019. PMID: 31474332 Free PMC article.
-
Evidence from randomised trials on the long-term effects of hormone replacement therapy.Lancet. 2002 Sep 21;360(9337):942-4. doi: 10.1016/S0140-6736(02)11032-4. Lancet. 2002. PMID: 12354487 Review.
Cited by
-
Menopausal Hormone Therapy, an Ever-Present Topic: A Pilot Survey about Women's Experience and Medical Doctors' Approach.Medicina (Kaunas). 2024 May 7;60(5):774. doi: 10.3390/medicina60050774. Medicina (Kaunas). 2024. PMID: 38792957 Free PMC article.
-
Evidence-based management of menopause.Aust Prescr. 2024 Apr;47(2):43-45. doi: 10.18773/austprescr.2024.017. Aust Prescr. 2024. PMID: 38737373 Free PMC article. No abstract available.
-
Genetic risk impacts the association of menopausal hormone therapy with colorectal cancer risk.Br J Cancer. 2024 Jun;130(10):1687-1696. doi: 10.1038/s41416-024-02638-2. Epub 2024 Apr 1. Br J Cancer. 2024. PMID: 38561434 Free PMC article.
-
Is There a Special Role for Ovarian Hormones in the Pathogenesis of Lobular Carcinoma?Endocrinology. 2024 Mar 29;165(5):bqae031. doi: 10.1210/endocr/bqae031. Endocrinology. 2024. PMID: 38551031 Free PMC article. Review.
-
Evaluation of Antioxidant Effects of Pumpkin (Cucurbita pepo L.) Seed Extract on Aging- and Menopause-Related Diseases Using Saos-2 Cells and Ovariectomized Rats.Antioxidants (Basel). 2024 Feb 16;13(2):241. doi: 10.3390/antiox13020241. Antioxidants (Basel). 2024. PMID: 38397839 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous